Endogenous PP2A inhibitor CIP2A degradation by chaperone-mediated autophagy contributes to the antitumor effect of mitochondrial complex I inhibition.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
27 06 2023
Historique:
received: 09 08 2022
revised: 15 04 2023
accepted: 23 05 2023
medline: 4 10 2023
pubmed: 8 6 2023
entrez: 8 6 2023
Statut: ppublish

Résumé

Combined inhibition of oxidative phosphorylation (OXPHOS) and glycolysis has been shown to activate a PP2A-dependent signaling pathway, leading to tumor cell death. Here, we analyze highly selective mitochondrial complex I or III inhibitors in vitro and in vivo to elucidate the molecular mechanisms leading to cell death following OXPHOS inhibition. We show that IACS-010759 treatment (complex I inhibitor) induces a reactive oxygen species (ROS)-dependent dissociation of CIP2A from PP2A, leading to its destabilization and degradation through chaperone-mediated autophagy. Mitochondrial complex III inhibition has analogous effects. We establish that activation of the PP2A holoenzyme containing B56δ regulatory subunit selectively mediates tumor cell death, while the arrest in proliferation that is observed upon IACS-010759 treatment does not depend on the PP2A-B56δ complex. These studies provide a molecular characterization of the events subsequent to the alteration of critical bioenergetic pathways and help to refine clinical studies aimed to exploit metabolic vulnerabilities of tumor cells.

Identifiants

pubmed: 37289585
pii: S2211-1247(23)00627-7
doi: 10.1016/j.celrep.2023.112616
pii:
doi:

Substances chimiques

Autoantigens 0
Protein Phosphatase 2 EC 3.1.3.16
CIP2A protein, human 0
Electron Transport Complex I EC 7.1.1.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112616

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Riccardo Cazzoli (R)

Department of Experimental Oncology, IEO IRCCS, Istituto Europeo di Oncologia, Milan, Italy.

Francesco Romeo (F)

Department of Experimental Oncology, IEO IRCCS, Istituto Europeo di Oncologia, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Isabella Pallavicini (I)

Department of Experimental Oncology, IEO IRCCS, Istituto Europeo di Oncologia, Milan, Italy.

Sebastiano Peri (S)

Department of Experimental Oncology, IEO IRCCS, Istituto Europeo di Oncologia, Milan, Italy.

Mauro Romanenghi (M)

Department of Experimental Oncology, IEO IRCCS, Istituto Europeo di Oncologia, Milan, Italy.

Juan Alberto Pérez-Valencia (JA)

Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; Medical Clinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Mildred-Scheel Early Career Center, National Center for Tumor Diseases Dresden (NCT/UCC) University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.

Eman Hagag (E)

Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; Medical Clinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Filippo Ferrucci (F)

Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; Medical Clinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Mildred-Scheel Early Career Center, National Center for Tumor Diseases Dresden (NCT/UCC) University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany.

Mohamed Elgendy (M)

Institute for Clinical Chemistry and Laboratory Medicine, University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; Medical Clinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Mildred-Scheel Early Career Center, National Center for Tumor Diseases Dresden (NCT/UCC) University Hospital and Faculty of Medicine, Technische Universität Dresden, Dresden, Germany; Laboratory of Cancer Cell Biology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague, Czech Republic.

Orazio Vittorio (O)

Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Randwick, NSW, Australia; School of Biomedical Sciences, UNSW Sydney, Randwick, NSW, Australia.

Salvatore Pece (S)

Department of Experimental Oncology, IEO IRCCS, Istituto Europeo di Oncologia, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Marco Foiani (M)

IFOM (Fondazione Istituto FIRC di Oncologia Molecolare), Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy.

Jukka Westermarck (J)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland; Institute of Biomedicine, University of Turku, Turku, Finland.

Saverio Minucci (S)

Department of Experimental Oncology, IEO IRCCS, Istituto Europeo di Oncologia, Milan, Italy; Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Milan, Italy. Electronic address: saverio.minucci@ieo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH